Scott Saxman

8.2k total citations · 4 hit papers
41 papers, 5.5k citations indexed

About

Scott Saxman is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Scott Saxman has authored 41 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Surgery, 18 papers in Pulmonary and Respiratory Medicine and 15 papers in Oncology. Recurrent topics in Scott Saxman's work include Lung Cancer Treatments and Mutations (12 papers), Testicular diseases and treatments (11 papers) and Lung Cancer Research Studies (6 papers). Scott Saxman is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Testicular diseases and treatments (11 papers) and Lung Cancer Research Studies (6 papers). Scott Saxman collaborates with scholars based in United States, Canada and Malaysia. Scott Saxman's co-authors include Lawrence H. Einhorn, Thomas F. Pajak, Jay S. Cooper, Anthony J. Cmelak, Julie A. Kish, John F. Ensley, Harold E. Kim, Christopher J. Schultz, Arlene A. Forastiere and Joseph B. Jacobs and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Scott Saxman

40 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

2004 2.3k citations Jay S. Cooper, Thomas F. Pajak et al. New England Journal of Medicine profile →
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

1999 542 citations Paul B. Chapman, Lawrence H. Einhorn et al. Journal of Clinical Oncology profile →
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

2008 534 citations Scott Saxman, John M. Kirkwood et al. Journal of Clinical Oncology profile →
Long-term Follow-up of the RTOG 9501/Intergroup Phase III Trial: Postoperative Concurrent Radiation Therapy and Chemotherapy in High-Risk Squamous Cell Carcinoma of the Head and Neck

2012 385 citations Jay S. Cooper, Qiang Zhang et al. International Journal of Radiation Oncology*Biology*Physics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott Saxman United States	21	2.5k	2.4k	2.2k	1.5k	1.2k	41	5.5k
Frédéric Peyrade France	29	3.3k 1.3×	1.5k 0.6×	2.2k 1.0×	2.5k 1.6×	897 0.7×	138	5.7k
Ranjan Sur Canada	18	3.0k 1.2×	2.2k 0.9×	2.6k 1.2×	3.0k 1.9×	1.3k 1.1×	68	6.4k
F. Cognetti Italy	27	2.3k 0.9×	1.9k 0.8×	2.2k 1.0×	1.3k 0.9×	933 0.8×	129	4.8k
Ricardo Hitt Spain	28	4.0k 1.6×	2.0k 0.8×	3.5k 1.6×	2.9k 1.9×	1.5k 1.2×	69	6.7k
Jan B. Vermorken Belgium	35	2.2k 0.9×	2.3k 1.0×	2.1k 0.9×	1.6k 1.0×	731 0.6×	96	5.6k
A. Dimitrios Colevas United States	51	3.4k 1.4×	2.2k 0.9×	2.6k 1.2×	2.1k 1.4×	1.6k 1.3×	197	7.6k
Missak Haigentz United States	37	1.8k 0.7×	1.6k 0.7×	1.7k 0.8×	903 0.6×	736 0.6×	121	3.8k
Bhadrasain Vikram United States	40	2.2k 0.9×	2.3k 1.0×	2.0k 0.9×	1.6k 1.0×	542 0.4×	148	5.9k
N. Azarnia United States	24	3.5k 1.4×	1.3k 0.6×	2.0k 0.9×	2.7k 1.8×	1.4k 1.1×	52	6.5k
Ranee Mehra United States	38	4.1k 1.7×	1.4k 0.6×	1.7k 0.8×	2.3k 1.5×	1.5k 1.2×	194	6.5k

Countries citing papers authored by Scott Saxman

Since Specialization

Citations

This map shows the geographic impact of Scott Saxman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Saxman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Saxman more than expected).

Fields of papers citing papers by Scott Saxman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Saxman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Saxman. The network helps show where Scott Saxman may publish in the future.

Co-authorship network of co-authors of Scott Saxman

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Saxman. A scholar is included among the top collaborators of Scott Saxman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Saxman. Scott Saxman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Edward S., Marcus A. Neubauer, Allen Lee Cohn, et al.. (2013). Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. The Lancet Oncology. 14(13). 1326–1336. 50 indexed citations

Cooper, Jay S., Qiang Zhang, Thomas F. Pajak, et al.. (2012). Long-term Follow-up of the RTOG 9501/Intergroup Phase III Trial: Postoperative Concurrent Radiation Therapy and Chemotherapy in High-Risk Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology*Biology*Physics. 84(5). 1198–1205. 385 indexed citations breakdown →

Zinner, Ralph, Scott Saxman, Guangbin Peng, Matthew Monberg, & Waldo Ortuzar. (2010). Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non–Small-Cell Lung Cancer of Nonsquamous Histology. Clinical Lung Cancer. 11(5). 352–357. 13 indexed citations

Lu, Charles, J. Jack Lee, Ritsuko Komaki, et al.. (2010). Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III Trial. JNCI Journal of the National Cancer Institute. 102(12). 859–865. 59 indexed citations

Bleyer, Archie, Michael Montello, Troy Budd, & Scott Saxman. (2005). National survival trends of young adults with sarcoma. Cancer. 103(9). 1891–1897. 143 indexed citations

Cooper, Jay S., Thomas F. Pajak, Arlene A. Forastiere, et al.. (2004). Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine. 350(19). 1937–1944. 2295 indexed citations breakdown →

Saxman, Scott. (1999). Oral Etoposide in Germ Cell Tumours. Drugs. 58(Supplement 3). 31–34. 5 indexed citations

Chapman, Paul B., Lawrence H. Einhorn, Michael L. Meyers, et al.. (1999). Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 17(9). 2745–2745. 542 indexed citations breakdown →

Saxman, Scott, et al.. (1998). A Phase II Trial of Vinorelbine in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology. 21(4). 398–400. 12 indexed citations

10.

Saxman, Scott, David Finch, R Gonin, & Lawrence H. Einhorn. (1998). Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience.. Journal of Clinical Oncology. 16(2). 702–706. 127 indexed citations

11.

Sandler, Alan, Scott Saxman, Douglas K. Heilman, et al.. (1998). Ifosfamide in the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology. 21(2). 195–197. 9 indexed citations

12.

Saxman, Scott, Craig R. Nichols, & Lawrence H. Einhorn. (1997). Pulmonary Toxicity in Patients With Advanced-Stage Germ Cell Tumors Receiving Bleomycin With and Without Granulocyte Colony Stimulating Factor. CHEST Journal. 111(3). 657–660. 51 indexed citations

13.

Saxman, Scott & D Seitz. (1997). Breast cancer associated with palmar fasciitis and arthritis.. Journal of Clinical Oncology. 15(12). 3515–3516. 14 indexed citations

14.

Saxman, Scott, Kathleen J. Propert, Lawrence H. Einhorn, et al.. (1997). Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.. Journal of Clinical Oncology. 15(7). 2564–2569. 393 indexed citations

15.

Saxman, Scott, C R Nichols, & Lawrence H. Einhorn. (1994). Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience.. Journal of Clinical Oncology. 12(7). 1390–1393. 74 indexed citations

16.

Saxman, Scott, Rafat Ansari, R. E. Drasga, et al.. (1992). Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer: A hoosier oncology group study. Cancer. 70(10). 2488–2492. 20 indexed citations

17.

Saxman, Scott, et al.. (1991). Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer. Investigational New Drugs. 9(3). 253–256. 20 indexed citations

18.

Saxman, Scott, Craig R. Nichols, Stephen D. Williams, Patrick J. Loehrer, & Lawrence H. Einhorn. (1991). Mediastinal yolk sac tumor. Journal of Thoracic and Cardiovascular Surgery. 102(6). 913–916. 9 indexed citations

19.

Harrington, Maureen A., et al.. (1991). Cloning and characterization of the murine promoter for the colony-stimulating factor-1-encoding gene. Gene. 102(2). 165–170. 43 indexed citations

20.

Nichols, Craig R., Scott Saxman, Stephen D. Williams, et al.. (1990). Primary mediastinal nonseminomatous germ cell tumors. A modern single institution experience. Cancer. 65(7). 1641–1646. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact